hrcak mascot   Srce   HID

Ostalo

WEIGHT LOSS DURING THERAPY WITH OLANZAPINE ORALLY DISINTEGRATING TABLETS: TWO CASE REPORTS

Oliver Kozumplik ; University Department, Vrapče Psychiatric Hospital, Bolnička cesta 32, Zagreb, Croatia
Suzana Uzun ; University Department, Vrapče Psychiatric Hospital, Bolnička cesta 32, Zagreb, Croatia
Miro Jakovljević ; University Department, Clinical Hospital Zagreb, Kišpatićeva 12, Zagreb, Croatia

Puni tekst: engleski, pdf (250 KB) str. 72-74 preuzimanja: 680* citiraj
APA 6th Edition
Kozumplik, O., Uzun, S. i Jakovljević, M. (2009). WEIGHT LOSS DURING THERAPY WITH OLANZAPINE ORALLY DISINTEGRATING TABLETS: TWO CASE REPORTS. Psychiatria Danubina, 21 (1), 72-74. Preuzeto s https://hrcak.srce.hr/32771
MLA 8th Edition
Kozumplik, Oliver, et al. "WEIGHT LOSS DURING THERAPY WITH OLANZAPINE ORALLY DISINTEGRATING TABLETS: TWO CASE REPORTS." Psychiatria Danubina, vol. 21, br. 1, 2009, str. 72-74. https://hrcak.srce.hr/32771. Citirano 26.11.2020.
Chicago 17th Edition
Kozumplik, Oliver, Suzana Uzun i Miro Jakovljević. "WEIGHT LOSS DURING THERAPY WITH OLANZAPINE ORALLY DISINTEGRATING TABLETS: TWO CASE REPORTS." Psychiatria Danubina 21, br. 1 (2009): 72-74. https://hrcak.srce.hr/32771
Harvard
Kozumplik, O., Uzun, S., i Jakovljević, M. (2009). 'WEIGHT LOSS DURING THERAPY WITH OLANZAPINE ORALLY DISINTEGRATING TABLETS: TWO CASE REPORTS', Psychiatria Danubina, 21(1), str. 72-74. Preuzeto s: https://hrcak.srce.hr/32771 (Datum pristupa: 26.11.2020.)
Vancouver
Kozumplik O, Uzun S, Jakovljević M. WEIGHT LOSS DURING THERAPY WITH OLANZAPINE ORALLY DISINTEGRATING TABLETS: TWO CASE REPORTS. Psychiatria Danubina [Internet]. 2009 [pristupljeno 26.11.2020.];21(1):72-74. Dostupno na: https://hrcak.srce.hr/32771
IEEE
O. Kozumplik, S. Uzun i M. Jakovljević, "WEIGHT LOSS DURING THERAPY WITH OLANZAPINE ORALLY DISINTEGRATING TABLETS: TWO CASE REPORTS", Psychiatria Danubina, vol.21, br. 1, str. 72-74, 2009. [Online]. Dostupno na: https://hrcak.srce.hr/32771. [Citirano: 26.11.2020.]

Sažetak
The aim of this article is to report weight loss in patients with schizophrenia after switching from olanzapine standard oral tablet (SOT) to olanzapine orally disintegrating tablets (ODT).
In the first case report, the patient was switched to olanzapine ODT in daily dosage of 20 mg, while in the second case report, the patient was switched to olanzapine ODT in daily dosage of 15 mg, and weight loss was similar (14 kg vs. 15 kg). Switching patients from olanzapine SOT to olanzapine ODT treatment resulted in significant weight loss that was maintained during 12 months in both case
reports. Further controlled clinical investigations are necessary to evaluate change in weight during treatment with olanzapine ODT, and to improve our understanding of this change.

Ključne riječi
olanzapine; schizophrenia; weight loss; treatment

Hrčak ID: 32771

URI
https://hrcak.srce.hr/32771

Posjeta: 904 *